These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 11380317

  • 1. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
    Horai Y, Kimura M, Furuie H, Matsuguma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T.
    Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
    Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, Morisawa T, Fukushima Y, Nakagawa K, Hasegawa J, Otsubo K, Ishizaki T.
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
    [Abstract] [Full Text] [Related]

  • 3. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y.
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.
    Hu YM, Mei Q, Xu XH, Hu XP, Hu NZ, Xu JM.
    World J Gastroenterol; 2006 Aug 07; 12(29):4750-3. PubMed ID: 16937451
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.
    Hu YM, Xu JM, Mei Q, Xu XH, Xu SY.
    Acta Pharmacol Sin; 2005 Mar 07; 26(3):384-8. PubMed ID: 15715938
    [Abstract] [Full Text] [Related]

  • 6. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2004 Oct 07; 76(4):290-301. PubMed ID: 15470328
    [Abstract] [Full Text] [Related]

  • 7. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S.
    Aliment Pharmacol Ther; 2002 Oct 07; 16(10):1811-7. PubMed ID: 12269976
    [Abstract] [Full Text] [Related]

  • 8. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
    Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T.
    Aliment Pharmacol Ther; 2001 Dec 07; 15(12):1929-37. PubMed ID: 11736724
    [Abstract] [Full Text] [Related]

  • 9. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T.
    J Gastroenterol Hepatol; 2002 Jul 07; 17(7):748-53. PubMed ID: 12121503
    [Abstract] [Full Text] [Related]

  • 10. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
    Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K.
    Pharm Res; 2001 Jun 07; 18(6):721-7. PubMed ID: 11474773
    [Abstract] [Full Text] [Related]

  • 11. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
    Dojo M, Azuma T, Saito T, Ohtani M, Muramatsu A, Kuriyama M.
    Dig Liver Dis; 2001 Nov 07; 33(8):671-5. PubMed ID: 11785712
    [Abstract] [Full Text] [Related]

  • 12. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S.
    Clin Pharmacol Ther; 2006 Jan 07; 79(1):144-52. PubMed ID: 16413249
    [Abstract] [Full Text] [Related]

  • 13. Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
    Lin CJ, Yang JC, Uang YS, Chern HD, Wang TH.
    Pharmacotherapy; 2003 Jun 07; 23(6):711-9. PubMed ID: 12820812
    [Abstract] [Full Text] [Related]

  • 14. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
    Sagar M, Tybring G, Dahl ML, Bertilsson L, Seensalu R.
    Gastroenterology; 2000 Sep 07; 119(3):670-6. PubMed ID: 10982760
    [Abstract] [Full Text] [Related]

  • 15. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2001 Nov 07; 70(5):484-92. PubMed ID: 11719736
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Lee SB, Park SJ, Ryu JK, Lee JK, Kim HJ, Bae JS, Jung HS, Park SM.
    Korean J Gastroenterol; 2003 Dec 07; 42(6):468-75. PubMed ID: 14695703
    [Abstract] [Full Text] [Related]

  • 17. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
    Itagaki F, Homma M, Yuzawa K, Nishimura M, Naito S, Ueda N, Ohkohchi N, Kohda Y.
    J Pharm Pharmacol; 2004 Aug 07; 56(8):1055-9. PubMed ID: 15285851
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
    Inamori M, Togawa J, Takahashi K, Yoneda M, Fujisawa N, Iwasaki T, Ozawa Y, Kikuchi T, Muramatsu K, Chiguchi G, Matsumoto S, Kawamura H, Abe Y, Kirikoshi H, Kobayashi N, Sakaguchi T, Takamura T, Nakajima A, Ueno N, Sekihara H.
    J Gastroenterol Hepatol; 2003 Sep 07; 18(9):1034-8. PubMed ID: 12911659
    [Abstract] [Full Text] [Related]

  • 19. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U.
    Int J Clin Pharmacol Ther; 2006 Jul 07; 44(7):297-302. PubMed ID: 16961157
    [Abstract] [Full Text] [Related]

  • 20. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
    Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T.
    Br J Clin Pharmacol; 2006 Mar 07; 61(3):309-14. PubMed ID: 16487224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.